Menu
.
A Generic infrastructure for developing tools for early, accurate and accessible diagnosis of human diseases
In today’s global healthcare landscape, there’s a pressing demand for technologies that allow for a much earlier diagnosis, when diseases can be cured, which, in turn also reduces treatment costs while relieving pressure on health systems.
However, the main obstacle to achieving this goal is developing technologies that are sensitive, precise, and readily available.
.
Current State of the Art in liquid Biopsy
The current state of liquid biopsy technology is primarily focused on sensitive cancer detection for early diagnosis and residual disease monitoring. The major players in the field are primarily concentrating their efforts on a single measurement, mainly genomics or DNA methylation-based technologies.
Diagnosis is largely based on markers derived from the tumor itself, and most efforts are geared towards complex and relatively costly technologies that require laboratory services.
.
A Multi-Omics platform for early pre-symptomatic detection of disease markers
LIQUIDBX consortium is developing an infrastructure for the development of a generic technological toolbox for the detection of biological markers and their integration into modular generic sensors for the early detection of diseases. The multi-omic sensors will identify signals coming from multiple biological elements including genomics, epigenomics, metabolomics, proteomics, the immune system and more.
Israel’s Innovation Authority backed Genome Editing Consortium
The LIQUIDBX consortium is supported with research and development grants from the Innovation Authority of Israel (IAI). The LIQUIDBX consortium operates under the Magnet Consortium track of the IAI.
The support of the Innovation Authority of Israel through the LIQUIDBX consortium enables the member companies to be at the forefront of the liquid biopsy field worldwide while recruiting leading scientists and deploying innovative technologies developed in Israel.
Solid-state nanopores (ssNPs) are single-molecule sensors capable of label-free quantification of different biomolecules…
LIQUIDBX members, Professors Yuval Dor, Tommy Kaplan and Ben Glaser announce breakthrough in liquid biopsy research.
Copyright 2023 LIQUIDBX – All Rights Reserved
Produced by Webzilla
